Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Stanley Schwartz

Endocrinology, Diabetes & Metabolism Ardmore, PA Medical Doctor

NPI 1649202078 CMS profile 347258

233 E Lancaster Ave, Suite 305, Ardmore, PA 19003

Open in the dashboard

General payments

$111,611

312 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Stanley Schwartz of Ardmore, PA is reported in the CMS Open Payments database as having received $111,611 across 312 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $11,969 35
2023 General $5,730 16
2022 General $41 1
2021 General $10,382 40
2020 General $11,762 28
2019 General $71,726 192

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stanley Schwartz
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Stanley Schwartz were reported at $0. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Stanley Schwartz Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $71,726 $494 $123–$2,253 $163
2020 $11,762 $335 $85–$1,841 $114
2021 $10,382 $398 $88–$1,981 $132
2022 $41 $364 $88–$1,568 $149
2023 $5,730 $420 $113–$1,614 $160
2024 $11,969 $440 $121–$1,646 $164
2025 $0 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Lilly USA, LLC $35,826 78 payments
  2. Janssen Pharmaceuticals, Inc $22,471 34 payments
  3. Merck Sharp & Dohme Corporation $18,289 27 payments
  4. Salix Pharmaceuticals, a division of Bausch Health US, LLC $17,293 67 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $12,531 28 payments
  6. Esperion Therapeutics, Inc. $2,087 6 payments
  7. Zealand Pharma US, Inc. $1,641 5 payments
  8. Novo Nordisk Inc $574 26 payments
  9. Janssen Scientific Affairs, LLC $155 4 payments
  10. BioCryst US Sales Co., LLC $125 1 payment
  11. Other $619 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $65,443 37 payments
  2. Consulting Fee $22,215 10 payments
  3. Travel and Lodging $14,518 58 payments
  4. Food and Beverage $4,705 199 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $4,650 4 payments
  6. Education $81 4 payments
Products named General payments · program years 2019–2024
  1. INVOKANA $22,597 35 payments
  2. STEGLATRO $18,219 21 payments
  3. JARDIANCE Diabetes $18,182 26 payments
  4. CYCLOSET $17,293 67 payments
  5. JARDIANCE Diabetes $12,531 28 payments
  6. ZEPBOUND $3,922 9 payments
  7. NEXLETOL $2,087 6 payments
  8. NEXLIZET $2,040 2 payments
  9. ZEGALOGUE $1,641 5 payments
  10. Ozempic $444 23 payments
  11. Other $1,431 70 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Internal Medicine: 777

Drug cost

$15,559

Median for Internal Medicine: $73,373

Branded share of claims

100%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 11 $15,559

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $3,922
$3,922 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

312 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record